From: Multilayer network analysis of the drugs development cycle in the global pharmaceutical industry
\(G_3\): Ownership | ||||
---|---|---|---|---|
Index | Size | Country | Primary industry | Bow tie |
1:1: | 8,860 | US (22.4) IND (8.8) CAN (6.2) CHN (5.8) GBR (5.4) JPN (5.1) | Asset management and custody banks (10.8) | IN (56.2) TE (42.8) |
1:2: | 2,761 | US (21.2) IND (9.1) CAN (6.7) AUS (6.1) CHN (5.1) GBR (5.1) | Asset management and custody banks (10.0) | IN (58.1) TE (40.9) |
1:5: | 2,674 | US (20.6) IND (9.1) CAN (7.6) GBR (5.5) CHN (5.4) AUS (5.3) JPN (5.1) | Asset management and custody banks (9.4) | IN (55.3) TE (43.5) |